Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 18/20 | 0.56 |
| ▸ | PDGFRA | P16234 | 13/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 9/20 | 0.56 |
| ▸ | FLT3 | P36888 | 5/20 | 0.56 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28341096 | 0.87 | CYP2A6 (0.50) | CSF1RPDGFRAPDGFRBFLT3CYP2C9 | |
| SCHEMBL16059710 | 0.86 | CSF1R (0.50) | CSF1RPDGFRAPDGFRBFLT3TGFBR1 | |
| SCHEMBL16028384 | 0.85 | CSF1R (0.43) | CSF1RPDGFRAPDGFRBFLT3CYP2C9 | |
| SCHEMBL16029184 | 0.85 | CSF1R (0.53) | CSF1RPDGFRAPDGFRBFLT3TGFBR1 | |
| SCHEMBL16028599 | 0.81 | LTA4H (0.43) | CSF1RPDGFRAPDGFRBFLT3TGFBR1 | |
| SCHEMBL28463024 | 0.81 | CSF1R (0.61) | CSF1RPDGFRAPDGFRBFLT3CYP2C9 | |
| SCHEMBL30022723 | 0.80 | CSF1R (0.59) | CSF1RPDGFRAPDGFRBFLT3CYP2C9 | |
| SCHEMBL16085814 | 0.80 | CSF1R (0.48) | CSF1RPDGFRAPDGFRBFLT3CYP2C9 | |
| SCHEMBL16028792 | 0.80 | CSF1R (0.59) | CSF1RPDGFRAPDGFRBFLT3CYP2C9 | |
| SCHEMBL16028485 | 0.80 | CSF1R (0.40) | CSF1RPDGFRAPDGFRBFLT3TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2968287-B1 | N-ACYL-N'-(PYRIDIN-2-YL) UREAS AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS LLC (US) | 2020-06-24 | — | — | EP | disclosed |
| EP-2968287-B1 | N-ACYL-N'-(PYRIDIN-2-YL) UREAS AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS LLC (US) | 2020-06-24 | — | — | EP | disclosed |
| US-9382228-B2 | N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382228-B2 | N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382228-B2 | N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2016-07-05 | — | — | US | disclosed |
| US-20160046619-A1 | IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS LLC (US) | 2016-02-18 | — | — | US | disclosed |
| US-20160046619-A1 | IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS LLC (US) | 2016-02-18 | — | — | US | disclosed |
| US-20160046619-A1 | IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS LLC (US) | 2016-02-18 | — | — | US | disclosed |
| EP-2968287-A2 | N-ACYL-N'-(PYRIDIN-2-YL) UREAS AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | Deciphera Pharmaceuticals, LLC (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9133183-B2 | Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2015-09-15 | — | — | US | disclosed |
| US-20140315917-A1 | IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140315917-A1 | IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140315917-A1 | IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140275080-A1 | N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275080-A1 | N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275080-A1 | N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2014145028-A2 | N-ACYL-N'-(PYRIDIN-2-YL) UREAS AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014145015-A2 | IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014145015-A2 | IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014145028-A2 | N-ACYL-N'-(PYRIDIN-2-YL) UREAS AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275080-A1 | N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities | KIT, CSF1R, CSF3R | CSF1R 2/4885PDGFRA 5/4885PDGFRB 6/4885 |
| US-20160046619-A1 | IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | CSF1R, KIT, CSF3R | CSF1R 1/4885PDGFRA 5/4885PDGFRB 6/4885 |
| US-20140315917-A1 | IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | CSF1R, KIT, CSF3R | CSF1R 1/4885PDGFRA 5/4885PDGFRB 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.